Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy

Uveal melanoma is the most common primary intraocular malignancy. The aim of this retrospective study was to report the results after ruthenium-106 (Ru-106) plaque brachytherapy for uveal melanoma in terms of tumor control, visual acuity, radiation-related complications, tumor recurrence, metastases...

Descripción completa

Detalles Bibliográficos
Autores principales: Cennamo, Gilda, Montorio, Daniela, D’ Andrea, Luca, Farella, Antonio, Matano, Elide, Giuliano, Mario, Liuzzi, Raffaele, Breve, Maria Angelica, De Placido, Sabino, Cennamo, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763327/
https://www.ncbi.nlm.nih.gov/pubmed/35047387
http://dx.doi.org/10.3389/fonc.2021.754108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763327/
https://www.ncbi.nlm.nih.gov/pubmed/35047387
http://dx.doi.org/10.3389/fonc.2021.754108

Ejemplares similares